


Sup figure 3



Supplementary information, Figure S3 (A) Re-expression of ectopically V5 tagged SLC3A2 in Y/T dbKO cells do not rescue SLC7A5 expression. Y/T dbKO cells expressing either V5 tagged SLC3A2 or vector control were lysed in non reducing buffer and blotted for the antibodies shown. **(B)** Re-expression of ectopically V5 tagged SLC7A5 or SLC7A7 in Y/T dbKO rescues hetero-oligomeric transporter complexes. Cell lysates from different cell lines as in Figure 2E were prepared in either non reducing buffer (no β -mercaptoethanol) or reducing buffer (containing β -mercaptoethanol) and blotted for V5. Note the incorporation of both SLC7A5 and SLC7A7 into high oligomeric complexes in none reducing buffers. **(C)** Gln/Leu mTORC1 activation is RagAB dependent. WT, RagAB dbKO, or RagAB dbKO cells overexpressing (OE) SLC7A5 were treated as illustrated. Cell lysates were obtained and Westerns blotted for the indicated abs. Note that pS6K levels are dramatically diminished in RagAB dbKO cells upon Gln/Leu stimulation compared to WT cells. **(D)** Differential requirement for YAP or TAZ expression for various YAP/TAZ target genes. qPCR of SLC7A5, or known YAP/TAZ target genes AMOTL2, CTGF and Cyr61 levels in WT, YAP KO, TAZ KO and Y/T dbKO cells.